United States-based Shepherd Therapeutics has collaborated with Mayo Clinic to advance research in rhabdomyosarcoma, a cancer that most often affects children, it was reported on Thursday.
Under the collaboration, both companies will use Shepherd Therapeutics' proprietary, next-generation precision-oncology platform, DELVE, to identify mechanisms for drug response and resistance in rhabdomyosarcoma (RMS) patients, and to identify new single drug and multi-drug combinations that have the potential to affect RMS care.
This RMS research project is being headed by the Mayo Clinic clinicians and scientists including Patricio Gargollo, MD, associate professor urology, paediatric urologist, Mayo Clinic, Candace Granberg, MD, assistant professor urology, paediatric urologist, Mayo Clinic and SHEPHERD Foundation Advisory Council member, and Fabrice Lucien-Matteoni, PhD, assistant professor of urology, Mayo Clinic.
Circio unveils circVec proof-of-concept
GSK releases decade-long data on Shingrix efficacy
BiVictriX receives FDA Orphan Drug Designation for AML treatment candidate
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
GSK's meningitis vaccine candidate accepted for FDA review
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
ProAxsis secures GBP1.8m investment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients